Mycobacterium tuberculosis and Tuberculosis: Pathogenesis, Clinical Disease, and Diagnosis

A young adult has had a cough for more than three weeks, now bringing up blood-streaked sputum, along with weight loss, night sweats, and a low-grade fever that returns each evening. A chest X-ray shows shadowing in the upper part of one lung. This is the classic picture of pulmonary tuberculosis, caused by an organism that can live quietly inside the body for years before it strikes: Mycobacterium tuberculosis.

Tuberculosis is one of the leading infectious causes of death worldwide and a major disease across South Asia. What makes it remarkable is its patience: the organism can hide inside the body's own immune cells, be walled off, and stay dormant for decades, then reactivate when defenses weaken. This page is about how M. tuberculosis causes disease, why it can be both latent and active, and how tuberculosis is diagnosed and why it is so hard to treat.

The organism

Mycobacterium tuberculosis is a slender, rod-shaped, acid-fast bacterium. It belongs to the genus Mycobacterium, whose defining waxy, mycolic-acid cell wall makes all its members acid-fast, slow-growing, and hard to treat; that shared biology is covered on the Mycobacterium overview. A few points specific to M. tuberculosis are:

• It is a strict aerobe, which is why it prefers the well-oxygenated upper parts of the lungs, the site of most reactivation disease.
• It is very slow-growing (dividing every 15 to 20 hours), so cultures take weeks and treatment takes months.
• It is carried in airborne droplet nuclei and survives well in dried form, which is central to how it spreads.
• It survives inside macrophages, the single most important fact about its pathogenesis, described below.

How tuberculosis spreads

TB spreads through the air. A person with active pulmonary (or laryngeal) TB coughs, sneezes, or speaks, releasing tiny droplet nuclei containing M. tuberculosis that stay suspended in the air and are inhaled by others. The organism's tough wall lets it survive in these dried droplets, and only a few bacilli need to reach the small airways to establish infection.

Several facts shape TB epidemiology and are worth holding:

• Transmission needs prolonged, close contact (household, crowded indoor settings) far more than brief exposure.
• Only active pulmonary/laryngeal TB is infectious. Latent TB is not contagious, and TB outside the lungs (for example, in lymph nodes or bone) generally does not spread person to person.
• TB is strongly linked to crowding, poverty, malnutrition, HIV, and diabetes, and is a major disease across South Asia, sub-Saharan Africa, and other high-burden regions. HIV is the single strongest risk factor for progressing from infection to disease.

How Mycobacterium tuberculosis causes disease

Tuberculosis is best understood as a long struggle between the organism surviving inside macrophages and the immune system trying to contain it. Almost every feature of TB follows from this.

The virulence strategy: survive inside the macrophage

M. tuberculosis has no classic toxins. Its power is its ability to survive inside the very cell meant to destroy it, the macrophage.

• When inhaled bacilli reach the alveoli, alveolar macrophages engulf them, as they would any inhaled particle.
• Normally a macrophage would kill the organism by fusing the phagosome (the bubble holding the bacterium) with a lysosome full of destructive enzymes. M. tuberculosis blocks this fusion (phagosome-lysosome fusion), so it survives and multiplies inside the macrophage.
• The waxy cell wall (cord factor, and other lipids) protects it and drives the inflammatory response.

So the organism turns the macrophage from a killer into a shelter and a vehicle.

The granuloma: the immune system walls it off

After a few weeks, the immune system mounts a cell-mediated (T-cell) response, and this is the turning point.

• T-cells activate the infected macrophages, and the immune cells organize into a granuloma (tubercle): a ball of activated macrophages (epithelioid cells and multinucleated giant cells) surrounded by lymphocytes, walling off the organism.
• In the center of the granuloma, the tissue dies in a characteristic cheese-like way called caseous necrosis ("caseation"), the hallmark of TB. The low-oxygen, acidic center slows the organism down but does not always kill it.

The granuloma is a double-edged outcome: it contains the infection (good), but it also preserves living organisms in a dormant state at its center (the seed of later reactivation).

The fork: latent vs active TB

What happens next defines the two faces of TB.

• In most people (about 90%), the granuloma successfully contains the organism. The person has latent TB infection: infected, immune-reactive (a positive tuberculin test), but not ill and not infectious. The organisms sit dormant, sometimes for life.
• In a minority, the immune system fails to contain it, either at first exposure (primary progressive TB, more common in young children and the immunocompromised) or years later when immunity wanes (reactivation / post-primary TB). The granulomas break down, release organisms, and active disease develops. This is why TB can strike decades after infection.

The immune-mediated damage

Crucially, much of the tissue destruction in TB, the lung cavities, the caseation, is caused by the body's own immune response, not by a bacterial toxin. The same immune reaction that contains the organism also damages the tissue. This explains why TB is a chronic, destructive, granulomatous disease.

Putting it together

Inhaled bacilli are engulfed by alveolar macrophages but survive inside them by blocking their killing machinery. The immune system responds by building granulomas that wall the organism off, with caseous necrosis at the center. In most people this contains the infection as latent TB. But living organisms persist in the granuloma, and if immunity later weakens (age, HIV, malnutrition, diabetes), they reactivate into active TB, breaking down the granuloma, cavitating the lung, and shedding organisms into the airways to spread to others. Latency, reactivation, caseation, and the chronic course are all the same struggle, macrophage shelter versus immune containment, playing out over time.

The clinical disease

Primary TB

The first infection, often in childhood. Usually it is contained with few or no symptoms, leaving only a small scar and a positive tuberculin test. The combination of the initial lung lesion plus the draining lymph node is called the Ghon (primary) complex. In young children and the immunocompromised, primary infection can progress directly to disease (primary progressive TB) or spread widely.

Latent TB infection

Infected but contained, symptom-free, and not infectious, with a positive tuberculin or IGRA test. A large fraction of the world's population has latent TB. The lifetime risk of reactivation is roughly 5 to 10% overall, but much higher with HIV.

Reactivation (post-primary) TB

The classic adult pulmonary TB, from reactivation of dormant organisms or reinfection. It favors the oxygen-rich upper lobes and causes cavities. The clinical picture is the chronic one in the hook: cough for more than 2 to 3 weeks, sputum that may be blood-streaked (hemoptysis), weight loss, night sweats, evening fever, and fatigue, the "constitutional" symptoms.

Extrapulmonary and disseminated TB

TB can affect almost any organ, especially when immunity is poor:

• Lymph nodes (the commonest extrapulmonary site; cervical node TB is called scrofula).
• Pleura, bone and spine (spinal TB is Pott's disease), kidney and genitourinary tract, meninges (TB meningitis, especially dangerous in children), abdomen, and pericardium.
• Miliary TB: widespread bloodborne dissemination producing countless tiny lesions (like millet seeds) across the lungs and other organs, a severe, life-threatening form.

Extrapulmonary and disseminated TB are more common in children and in people with HIV or other immunosuppression.

How tuberculosis is diagnosed

Diagnosis combines clinical suspicion with laboratory tests, and because M. tuberculosis is slow to culture, rapid methods are important. This is a summary; the full workflow and each method is described in laboratory diagnosis of M. tuberculosis infection article.

• Acid-fast smear microscopy of sputum (Ziehl-Neelsen or fluorescent auramine) is fast and cheap but needs many organisms, so a negative smear does not exclude TB.
• Molecular testing, above all GeneXpert MTB/RIF, detects M. tuberculosis and rifampicin resistance from sputum within hours and is now a frontline test.
• Culture (on Lowenstein-Jensen medium or faster liquid systems) is the reference standard and allows drug-susceptibility testing, but takes weeks.
• Tuberculin skin test (Mantoux) and IGRA detect the immune response, indicating infection (latent or active) but not distinguishing the two; they support the diagnosis rather than confirm active disease. See the tuberculin skin test page.
• Chest X-ray supports the diagnosis (upper-lobe disease, cavities, miliary pattern) but is not specific.

The complete TB diagnostic workflow, how these fit together, is on the M. tuberculosis lab diagnosis page.

Treatment and drug-resistant TB

Why treatment is long and combined. Because M. tuberculosis grows slowly, survives inside cells, and persists in a dormant state in granulomas, it cannot be cleared quickly. TB is treated with a combination of several drugs for months (the standard first-line drugs are isoniazid, rifampicin, pyrazinamide, and ethambutol, given in an intensive phase then a continuation phase). Using a single drug, or stopping early, both lead to relapse and resistance. Directly observed therapy is used to support completion. Specific doses and durations are clinical decisions and are not covered here.

Drug resistance is the central modern problem:

• Multidrug-resistant TB (MDR-TB): resistant to at least isoniazid and rifampicin, the two most important first-line drugs. It requires longer treatment with more toxic second-line drugs.
• Extensively drug-resistant TB (XDR-TB): MDR plus resistance to key second-line drugs, leaving very few options.

Resistance arises largely from incomplete or improper treatment, which is why supervised, complete, combination therapy is the foundation of TB control. This is a serious and growing problem across South Asia.

Prevention. The BCG vaccine (a live attenuated M. bovis strain) is given in many high-burden countries and reduces severe childhood TB (miliary and TB meningitis), though its protection against adult pulmonary TB is variable. Detecting and treating active cases, and treating latent TB in high-risk people, are the other pillars of control.

How to remember

It hides inside the macrophage. The one fact that unlocks TB: the organism survives inside the macrophage meant to kill it, by blocking the phagosome from fusing with the lysosome. Shelter, not destruction. Everything else, latency, reactivation, the granuloma, follows from this.

The granuloma both saves and betrays you. The granuloma walls off the organism (containment, latent TB), but it also keeps living organisms alive at its center, ready to reactivate later. It is a prison that keeps the prisoner alive. That double role is why TB can return decades later.

Latent vs active: contained or broken out. Latent TB is the organism walled off, silent, not infectious, positive skin test. Active TB is the wall breaking down, ill, infectious (if pulmonary), cavitating the upper lung. The fork between them is whether immunity holds.

Upper lobes, because it loves oxygen. M. tuberculosis is a strict aerobe, so reactivation TB settles in the oxygen-rich upper lobes and cavitates there. Aerobe, apex.

Damage is your own immune system. The cavities and caseation are made largely by your immune response, not a bacterial toxin. TB destroys tissue through the fight, not through poison.

Slow bug, long combined treatment, resistance if you cut it short. Slow growth and intracellular persistence mean months of multiple drugs. Stop early or use one drug, and you breed MDR-TB.

Key exam facts in one table

Where students get confused

Infection is not the same as disease. Being infected with M. tuberculosis (latent TB) is not the same as having tuberculosis (active disease). Most infected people never become ill and are not infectious. TB control distinguishes the two carefully.

Latent TB is not contagious. Only active pulmonary or laryngeal TB spreads. People with latent TB, or with extrapulmonary TB, generally do not transmit the organism. Students often assume anyone "with TB" is infectious.

The tuberculin test shows exposure, not active disease. A positive Mantoux or IGRA means the immune system has met M. tuberculosis (infection, latent or active, or past BCG). It does not by itself mean active TB, and it does not distinguish latent from active.

The granuloma is protective and dangerous. It walls the organism off (containing infection) but also shelters living organisms for later reactivation. It is not simply "the body winning."

The damage is immune-mediated. TB's tissue destruction comes largely from the host immune response, not a toxin. This is why TB is a chronic granulomatous disease rather than an acute toxin illness.

Why treatment is so long, and resistance so easy to create. The organism's slow growth and intracellular, dormant persistence mean months of multiple drugs. Shortening or simplifying treatment breeds MDR-TB. This is the reason for directly observed, complete, combination therapy.

BCG does not reliably prevent adult pulmonary TB. It mainly protects young children against severe forms (miliary, meningitis). A vaccinated adult is not reliably protected against pulmonary TB, and prior BCG can complicate tuberculin interpretation.

References

1. Tille, P. M. (2022). Bailey & Scott's Diagnostic Microbiology (15th ed.). Elsevier.
2. Procop, G. W., et al. (2017). Koneman's Color Atlas and Textbook of Diagnostic Microbiology (7th ed.). Wolters Kluwer.
3. Murray, P. R., Rosenthal, K. S., & Pfaller, M. A. (2020). Medical Microbiology (9th ed.). Elsevier.
4. World Health Organization. (current). Global Tuberculosis Report. WHO. https://www.who.int/teams/global-tuberculosis-programme/tb-reports